Rinascera launches with two rare genetic skin disease therapies

Source Summary

Rinascera Therapeutics Inc. has secured enough initial funding to acquire two drugs for rare genetic skin diseases, despite stalled development with their previous owners. The company, whose name comes from the Latin root renasci – to be born again, was incubated by Olive Tree Capital, which led the seed round with participation from Civilization Ventures and Toba Capital.